drugset / Trial / NCT01915537
Infliximab and Classic DMARDs in the Rheumatoid Arthritis Patients
Unknown
170 enrolled
Zhang, Xiao, M.D.
Central South University · collabTianjin Medical University General Hospital · collabXijing Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A prospective, multi-centric, cohort study to observe the efficacy difference between intensive classic DMARDs and Infliximab(IFX) with methotrexate(MTX) treatment in sever rheumatoid arthritis(RA) 28 joints disease activity score\>5.1(DAS28\>5.1) patients with poor prognostic factors.Primary objective is compare the difference of clinical remission rate between classic DMARDs and Infliximab with MTX treatment in severe RA patients with poor prognostic factors at week 30.
Timeline
- Start
- 2013-08
- Primary completion
- 2015-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HCQ | Unknown | 200 mg | — |
| Subject | HCQ | Unknown | 400 mg | — |
| Subject | Infliximab | Monoclonal antibody | 3 mg/kg | — |
| Subject | LEF | Unknown | 20 mg | — |
| Subject | Thunder God Vine | Unknown | 40 mg | — |
| Subject | Thunder God Vine | Unknown | 60 mg | — |
| Background | MTX | Unknown | 10 mg | — |
| Background | MTX | Unknown | 15 mg | — |